Good morning, everyone, and how are you today? We are just fine, thank you, especially since the Pharmalot campus is unusually quiet this morning, since the short person is elsewhere, enjoying a mini-break from the local schoolhouse. As for us, we are pursuing our usual routine and relying on cups of stimulation for assistance. In the interest of full disclosure, our choice is apple cider donut. Feel free to join us. Meanwhile, there is much to do and, no doubt, you can relate. This is a busy time, yes? So here are some tidbits.
President Trump is expected to name former Eli Lilly (LLY) executive Alex Azar to lead the Department of Health and Human Services, according to various reports. Azar, who worked at the drug maker for much of the past decade, was president of Lilly U.S. operations until earlier this year, and served as HHS Deputy Secretary under former President George W. Bush.
The supplies of thousands of medicines are at risk if the U.K. leaves the European Union without a trade deal, European drug makers warn. Some phase of manufacturing for more than 2,600 drugs is conducted in the U.K., 45 million patient packs are supplied to other European countries each month, and 37 million flow in the opposite direction. A survey by the European Federation of Pharmaceutical Industries and Associations found 45 percent of drug makers expect trade delays if the U.K. and Europe return to World Trade Organization rules after Brexit.
Athenex objects … novel to have a pharma company complain about an (most probably) off-label use, if I may observe.
Comments are closed.